| Form | Liquid |
|---|
| Host Species | Humanized |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG4-kappa-[scFv]2 |
|---|
| Purity | >95% as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 0.71 mg/ml |
|---|
| Endotoxin Level | Please contact with the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human |
|---|
| Target | CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | Q16552 & Q9Y275 |
|---|
| Background | Tibulizumab (LY-3090106) is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
|
|---|
| Alternative Names | Bispecific, LY 3090106, LY-3090106, LY3090106, 1849636-24-3 |
|---|
| Species | Human |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|